This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Search results
From Proteopedia
You searched for Crizotinib
There is no page with the exact title "Crizotinib". The search results for "Crizotinib" are displayed below. You can create a page titled Crizotinib (by clicking on the red link).
For more information about searching Proteopedia, see Help.
To exclude pages titled with 4-character PDB codes, use the checkbox "only Human created pages" at the bottom of this page.
Showing below up to 20 results starting with #1.
View (previous 20) (next 20) (20 | 50 | 100 | 250 | 500)
Article title matches
- Category:Crizotinib (41 bytes)
1: List of pages with the keyword Crizotinib - Image:Crizotinib Structure.png (32 bytes)
1: Structure of the drug Crizotinib
Page text matches
- 3zbf (4,763 bytes)
2: ...cture of Human ROS1 Kinase Domain in Complex with Crizotinib==
16: ...g cancers with ROS1 translocations. Resistance to crizotinib developed in a patient with metastatic lung adeno...
18: Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1.,Awad MM, Katayama R... - 2wgj (7,760 bytes)
26: ... the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro...
28: Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibi... - 2wkm (7,780 bytes)
26: ... the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro...
28: Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibi... - 2xp2 (7,403 bytes)
2: ... Human Anaplastic Lymphoma Kinase in Complex with Crizotinib (PF-02341066)==
26: ... the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro...
28: Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibi... - Category:Crizotinib (41 bytes)
1: List of pages with the keyword Crizotinib - 2yfx (6,261 bytes)
2: ...Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib==
16: ...inical PK and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).
18: ...s to overcome clinical ALK mutations resistant to crizotinib.,Huang Q, Johnson TW, Bailey S, Brooun A, Bunker ... - 2yhv (5,979 bytes)
15: ...inical PK and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).
17: ...s to overcome clinical ALK mutations resistant to crizotinib.,Huang Q, Johnson TW, Bailey S, Brooun A, Bunker ... - Student Project 7 for UMass Chemistry 423 Spring 2015 (14,430 bytes)
3: ='''MTH1/crizotinib'''=
9: ... align='right' caption='Basic Structure of MTH1/S-crizotinib' scene='48/483888/Basic/1' />
17: ...r in colon carcinoma cells is activated. When (S)-Crizotinib inhibits MTH1, the protein can no longer function...
20: ... align='right' caption='Basic Structure of MTH1/S-crizotinib 4c9x' scene='48/483888/Basic/1' />
22: <br> MTH1/S-crizotinib is a member of a protein family of phosphorohydro... - Sandbox Reserved 432 (8,052 bytes)
13: ...keeper L1196M mutation that occurs in response to crizotinib.<ref>DOI: 10.18632/oncotarget.2055</ref>
14: ... the point mutations created from a resistance to crizotinib.
16: ... created in response to the first generation drug crizotinib.
31: ...) gatekeeper mutation which would ultimately make crizotinib and alectinib obsolete ROS1 inhibitors. The cryst...
38: ...ibitors, PF-06463922 is 10-times more potent than crizotinib and foretinib and 100-fold more potent than eithe... - 4anl (5,979 bytes)
15: ...inical PK and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).
17: ...s to overcome clinical ALK mutations resistant to crizotinib.,Huang Q, Johnson TW, Bailey S, Brooun A, Bunker ... - 4anq (6,262 bytes)
2: ...Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib==
16: ...inical PK and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).
18: ...s to overcome clinical ALK mutations resistant to crizotinib.,Huang Q, Johnson TW, Bailey S, Brooun A, Bunker ... - 4ans (4,859 bytes)
2: ...Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib== - 4joa (6,216 bytes)
16: ... contrast to that of known ALK inhibitors such as Crizotinib and NVP-TAE684 which occupy the ribose binding po... - 4mkc (6,737 bytes)
16: ...ing marked efficacy of ceritinib in patients with crizotinib-resistant disease.
18: The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.,Friboul... - 4c9w (4,879 bytes)
2: ==Crystal structure of NUDT1 (MTH1) with R-crizotinib==
14: ... growth in animal models. Our results propose (S)-crizotinib as an attractive chemical entity for further pre-...
16: Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.,Huber KV, Salah E, Rad... - 4c9x (4,851 bytes)
2: ==Crystal structure of NUDT1 (MTH1) with S-crizotinib==
14: ... growth in animal models. Our results propose (S)-crizotinib as an attractive chemical entity for further pre-...
16: Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.,Huber KV, Salah E, Rad... - 4ccb (6,380 bytes)
16: ...inical PK and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).
18: ...s to overcome clinical ALK mutations resistant to crizotinib.,Huang Q, Johnson TW, Bailey S, Brooun A, Bunker ... - 4ccu (6,408 bytes)
16: ...inical PK and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).
18: ...s to overcome clinical ALK mutations resistant to crizotinib.,Huang Q, Johnson TW, Bailey S, Brooun A, Bunker ... - 4cd0 (6,454 bytes)
16: ...inical PK and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).
18: ...s to overcome clinical ALK mutations resistant to crizotinib.,Huang Q, Johnson TW, Bailey S, Brooun A, Bunker ... - 4cli (7,025 bytes)
16: Although crizotinib demonstrates robust efficacy in ALK positive NSCL...
View (previous 20) (next 20) (20 | 50 | 100 | 250 | 500)
You may also try
